, Tracking Stock Market Picks
Enter Symbol:
Rating: PRXL
Buy $82
up 34.00 %

Parexel International Corporation (NASDAQ: PRXL) reiterated to Buy with price target $82 by UBS

Wednesday,  Jun 24, 2015  12:25 PM ET by Betsy O'Brien Harrison

UBS reiterated Parexel International Corporation (NASDAQ: PRXL) to Buy with price target $82. Previously UBS reiterated Parexel International Corporation (NASDAQ: PRXL) to Buy with price
target $58 on 09/17/2013, when the stock price was $50.03. Since then, Parexel International Corporation's stock price has gained 34% as of 06/24/2015's recent price of $67.15.
If you would have followed the previous UBS's recommendation on PRXL, you would have gained 34% of your investment in 645 days.

Parexel International Corporation is one of the largest biopharmaceutical outsourcing organizations in the world, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. With a commitment to providing solutions that expedite time-to-market and peak market penetration, PAREXEL has developed significant expertise in clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, industry training and publishing and other drug development consulting services. Its information technology subsidiary, Perceptive Informatics, Inc., develops and offers a portfolio of innovative technology-based products and services that facilitate clinical drug development and are designed to decrease time to peak sales.

UBS is the leading global wealth manager, a top tier investment banking and securities firm, and one of the largest global asset managers. In Switzerland, UBS is the market leader in retail and commercial banking. With headquarters in Zurich and Basel, Switzerland, UBS operates in over 50 countries and from all major international centers. UBS employs more than 80,000 people.

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy